Influx Healthtech Ltd
Incorporated in September 2020, Influx Healthtech Limited is a healthcare-focused company specialising in contract manufacturing.[1]
- Market Cap ₹ 458 Cr.
- Current Price ₹ 198
- High / Low ₹ 208 / 120
- Stock P/E 25.8
- Book Value ₹ 39.0
- Dividend Yield 0.00 %
- ROCE 60.2 %
- ROE 45.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 57.9%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 79.1 to 113 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 59 | 76 | 100 | 105 | |
| 0 | 53 | 65 | 83 | 84 | |
| Operating Profit | 0 | 6 | 11 | 17 | 21 |
| OPM % | 11% | 14% | 17% | 20% | |
| 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 2 | 3 |
| Profit before tax | 0 | 6 | 10 | 15 | 18 |
| Tax % | 26% | 26% | 25% | 25% | |
| 0 | 4 | 7 | 11 | 13 | |
| EPS in Rs | 0.00 | 1,800.00 | 2,880.00 | 4,452.00 | 7.37 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 44% |
| TTM: | 20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 58% |
| Last Year: | 45% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.03 | 0.03 | 0.03 | 0.03 | 18 | 23 |
| Reserves | 0 | 4 | 12 | 23 | 18 | 67 |
| 0 | 1 | 1 | 0 | 0 | 0 | |
| -0 | 12 | 16 | 18 | 34 | 23 | |
| Total Liabilities | 0 | 18 | 28 | 41 | 70 | 114 |
| 0 | 3 | 6 | 14 | 19 | 24 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 34 |
| 0 | 15 | 22 | 27 | 52 | 55 | |
| Total Assets | 0 | 18 | 28 | 41 | 70 | 114 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 0 | 4 | 7 | 9 | 7 | |
| 0 | -3 | -5 | -8 | -9 | |
| 0 | 1 | 0 | -1 | -0 | |
| Net Cash Flow | 0 | 1 | 2 | 0 | -2 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 64 | 66 | 58 | 113 | |
| Inventory Days | 14 | 18 | 41 | 112 | |
| Days Payable | 88 | 123 | 106 | 248 | |
| Cash Conversion Cycle | -10 | -39 | -6 | -24 | |
| Working Capital Days | 2 | 1 | 15 | 46 | |
| ROCE % | 237% | 111% | 85% | 60% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
12 November 2025 - Posted earnings-call audio (Nov 12, 2025) at www.influxhealthtech.com/wp-content/uploads/2025/11/10037509.mp3.
-
Investor Presentation
12 November 2025 - H1 FY26 results: revenue ₹66.8cr (+39%), EBITDA ₹14.7cr, PAT ₹10.0cr; capacity expansion, IPO proceeds plans.
-
Outcome of Board Meeting
12 November 2025 - Approved unaudited results for half-year ended Sep 30, 2025; issue proceeds utilized Rs1,562.51L, unutilized Rs3,361.47L.
-
Outcome of Board Meeting
12 November 2025 - Approved H1 results (Sep 30, 2025); limited review; Rs3,361.47 lakh unutilized issue proceeds.
-
Analysts/Institutional Investor Meet/Con. Call Updates
4 November 2025 - Earnings call Nov 12, 2025 4:00pm IST for H1 FY26 unaudited results.
Business Profile[1]
The company operates as a Contract Development and Manufacturing Organization (CDMO) catering to B2B clients in nutraceuticals, cosmetics, ayurvedic/herbal products, veterinary feed supplements, and homecare products.
Its core competency is offering end-to-end manufacturing services, including product formulation, development, regulatory support, and commercialization.